PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-142.73%
Negative net income growth while TRAW stands at 27.43%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
55.79%
Some D&A expansion while TRAW is negative at -63.89%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
71.34%
Deferred tax of 71.34% while TRAW is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-22.08%
Both cut yoy SBC, with TRAW at -41.94%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
83.34%
Slight usage while TRAW is negative at -132.99%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.76%
Lower AP growth vs. TRAW's 292.94%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-41.25%
Both reduce yoy usage, with TRAW at -139.29%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-22.08%
Negative yoy while TRAW is 0.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
9.39%
Operating cash flow growth at 50-75% of TRAW's 14.01%. Martin Whitman would worry about lagging operational liquidity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.94%
We cut debt repayment yoy while TRAW is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-35.14%
Negative yoy issuance while TRAW is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.